27590051|t|Generation and analyses of human synthetic antibody libraries and their application for protein microarrays
27590051|a|Antibody -based proteomics offers distinct advantages in the analysis of complex samples for discovery and validation of biomarkers associated with disease. However, its large-scale implementation requires tools and technologies that allow development of suitable antibody or antibody fragments in a high-throughput manner. To address this we designed and constructed two human synthetic antibody fragment (scFv) libraries denoted HelL-11 and HelL-13. By the use of phage display technology, in total 466 unique scFv antibodies specific for 114 different antigens were generated. The specificities of these antibodies were analyzed in a variety of immunochemical assays and a subset was further evaluated for functionality in protein microarray applications. This high-throughput approach demonstrates the ability to rapidly generate a wealth of reagents not only for proteome research, but potentially also for diagnostics and therapeutics. In addition, this work provides a great example on how a synthetic approach can be used to optimize library designs. By having precise control of the diversity introduced into the antigen - binding sites, synthetic libraries offer increased understanding of how different diversity contributes to antibody binding reactivity and stability, thereby providing the key to future library optimization.
27590051	0	10	Generation	T052	C3146294
27590051	15	23	analyses	T062	C0936012
27590051	27	32	human	T016	C0086418
27590051	33	61	synthetic antibody libraries	T170	C0598139
27590051	72	83	application	T169	C4048755
27590051	88	107	protein microarrays	T075	C1136348
27590051	108	116	Antibody	T116,T129	C0003241
27590051	124	134	proteomics	T091	C0872252
27590051	169	177	analysis	T062	C0936012
27590051	189	196	samples	T077	C2347026
27590051	201	210	discovery	T052	C1880355
27590051	215	225	validation	T062	C1519941
27590051	229	239	biomarkers	T201	C0005516
27590051	240	255	associated with	T080	C0332281
27590051	256	263	disease	T047	C0012634
27590051	290	304	implementation	T052	C1708476
27590051	314	319	tools	T073	C0336791
27590051	324	336	technologies	T063	C1513384
27590051	348	359	development	T169	C1527148
27590051	372	380	antibody	T116,T129	C0003241
27590051	384	402	antibody fragments	T116,T129	C0003241
27590051	408	430	high-throughput manner	T170	C0872047
27590051	480	485	human	T016	C0086418
27590051	486	530	synthetic antibody fragment (scFv) libraries	T170	C0598139
27590051	539	546	HelL-11	T116,T129	C0003241
27590051	551	558	HelL-13	T116,T129	C0003241
27590051	574	598	phage display technology	T063	C3494191
27590051	620	635	scFv antibodies	T116,T129	C0003241
27590051	663	671	antigens	T129	C0003320
27590051	715	725	antibodies	T116,T129	C0003241
27590051	756	777	immunochemical assays	T059	C0519671
27590051	834	852	protein microarray	T075	C1136348
27590051	853	865	applications	T169	C4048755
27590051	872	896	high-throughput approach	T170	C0872047
27590051	944	950	wealth	T080	C0699759
27590051	954	962	reagents	T130	C0034760
27590051	976	984	proteome	T116,T123	C0751973
27590051	985	993	research	T062	C0035168
27590051	1020	1031	diagnostics	T062	C1511890
27590051	1036	1048	therapeutics	T061	C0087111
27590051	1150	1165	library designs	T170	C0598139
27590051	1200	1209	diversity	T080	C1880371
27590051	1230	1237	antigen	T129	C0003320
27590051	1240	1253	binding sites	T192	C0005456
27590051	1255	1274	synthetic libraries	T170	C0598139
27590051	1322	1331	diversity	T080	C1880371
27590051	1347	1355	antibody	T116,T129	C0003241
27590051	1356	1374	binding reactivity	T052	C1145667
27590051	1379	1388	stability	T080	C0205360
27590051	1426	1433	library	T170	C0598139
27590051	1434	1446	optimization	T052	C2698650